Orforglipron Orforglipron (Eli Lilly) is a novel oral GLP-1 receptor agonist that is currently in phase 3 clinical trials
Some semaglutide users report that the aroma of foods they once loved becomes off-putting or overwhelming
April 22 Product: Abeona Therapeutics prademagene zamikeracel Indication: Recessive dystrophic epidermolysis bullosa Chemistry, manufacturing and controls (CMC) issues led the FDA to reject Abeona Therapeutics investigational gene-corrected cell therapy prademagene zamikeracel (pz-cel) in recessive dystrophic epidermolysis bullosa, a rare disorder that causes painful blistering and erosion of the skin
But production declines with age, stress, illness, toxin exposure, and poor nutrition
But its a crowded space with Danones Activia getting a brand refresh to better position it to younger consumers, and Chobani successfully betting on its clean-label USP standing out will increasingly come down to functionality
The Evolution of GLP-1 Therapies: From Gila Monster Venom to Medications Exenatide: The First GLP-1 Agonist The journey from Gila monster venom to approved medication began with the synthesis of exenatide in the late 1990s
